Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday

Key Points

• Summit Therapeutics is expected to report Q3 2026 results after market close on October 19. Analysts forecast a loss of $0.2871 per share and revenue of approximately $0.07 million.
• The company reported a Q2 loss of $0.28 per share, missing consensus by $0.01, and analysts expect full-year losses of $1.20 per share.
• Despite mixed analyst views, Summit has a consensus “Moderate Buy” rating and a $28.61 target price. Its lead drug candidate, ivonescimab, is being tested for solid tumors including non-small cell lung cancer.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Monday, October 19th. Analysts expect Summit Therapeutics to post earnings of ($0.2871) per share and revenue of $0.07 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, October 19, 2026 at 8:00 AM ET.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, analysts expect Summit Therapeutics to post ($1.20) EPS for the current fiscal year and ($1.25) EPS for the next fiscal year.

Summit Therapeutics Stock Performance

Shares of SMMT stock opened at $17.59 on Monday. The company's fifty day moving average price is $15.55 and its 200-day moving average price is $16.41. The stock has a market cap of $14.07 billion, a PE ratio of -15.71 and a beta of -1.51. Summit Therapeutics has a 12 month low of $12.07 and a 12 month high of $29.23.

Analyst Ratings Changes

SMMT has been the topic of several research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Summit Therapeutics in a research note on Friday, July 17th. Citigroup reaffirmed a "buy" rating and set a $43.00 target price (up from $40.00) on shares of Summit Therapeutics in a research note on Friday, September 25th. Jefferies Financial Group reaffirmed a "buy" rating and set a $30.00 target price on shares of Summit Therapeutics in a research note on Tuesday, September 29th. HC Wainwright reiterated a "neutral" rating on shares of Summit Therapeutics in a report on Wednesday, September 30th. Finally, Wall Street Zen raised Summit Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 5th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.61.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company's lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer.

Summit obtained exclusive rights from Akeso, Inc to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.